Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Therapeutic developments targeting acute myeloid leukemia (AML) have been in the
pipeline for five decades and have recently resulted in the approval of multiple targeted …

Proper subcellular localization is crucial for the functioning of biomacromolecules, including
proteins and RNAs. Nuclear transport is a fundamental cellular process that regulates the …

High grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBCL-DH) represents
an uncommon B-cell lymphoma (BCL) with aggressive clinical courses and poor prognosis …

Programmed cell death (PCD) is a process that occurs naturally in cells in response to
different endogenous or exogenous factors and facilitated by specific proteins. The three …

SF3B1 mutations frequently occur in cancer yet lack targeted therapies. Clinical trials of
XPO1 inhibitors, selinexor and eltanexor, in high-risk myelodysplastic neoplasms (MDS) …

XPO1 is an influential member of the nuclear transporter protein family. The proteins and
RNA transported by XPO1 are related to the occurrence and development of many diseases …

Chromosome Region Maintenance 1 (CRM1), also known as Exportin 1 (XPO1), is a protein
that is critical for transport of proteins and RNA to the cytoplasm through the nuclear pore …

ABSTRACT Background Exportin 1 (XPO1) inhibitors are being developed as a new agent
for anti-cancer therapies. This study aimed to broadly portray the adverse event (AE) profile …

Highlights•Management of myelodysplastic neoplasms (MDS) presents a complex
challenge, requiring tailored, individualized approaches.•Therapeutic options for MDS …